Biotech Values

[DewDiligence]

ENTA—...with approval baked into the price, what will it take to see a pop in the stock? Is it a matter of the analysts upgrading their expectations of the abbv/enta HCV market share from 15-20% to 35-40%?

More so than the analysts’ reports, the general publicity surrounding the approval of ABBV/ENTA’s regimen will attract attention to ENTA, which remains a stock that doesn’t get much.

…if they don't get a 12-week label for cirrhotic patients do you think we will see a downturn in stock price?

It depends on the label in its entirety. There are too many permutations to speculate about this with much confidence.